Who
Joseph M. Patti
Director
Company insider
Files Form 4 as: Director, Armata Pharmaceuticals; CEO, Vaxart; Chief Scientific Officer, Inhibitex.
In numbers
- Trades disclosed
- 70
- Buys
- 7
- Sells
- 5
- Bought
- $140K
- Sold
- $2.6M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 10 Jan 2006
- Last trade
- 9 Mar 2026
- Last filed
- 11 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Mar 2026filed 11 Mar 2026 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,640 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,640 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,343 at $0.00 | filing |
| 14 Mar 2024filed 18 Mar 2024 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,666 at $0.00 | filing |
| 14 Mar 2024filed 18 Mar 2024 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,343 at $0.00 | filing |
| 21 Dec 2023filed 26 Dec 2023 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,461 at $0.00 | filing |
| 13 Apr 2022filed 15 Apr 2022 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
| 7 Jun 2021filed 9 Jun 2021 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 8 Dec 2020filed 9 Dec 2020 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 22 May 2019filed 24 May 2019 | ARMP Armata Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,383 at $0.00 | filing |
| 3 Apr 2017filed 5 Apr 2017 | Vaxartoption or derivative · Biotechnology | SEC FORM 4 Code A | $429K650,000 at $0.66 | filing |
| 11 Aug 2016filed 12 Aug 2016 | Vaxartoption or derivative · Biotechnology | SEC FORM 4 Code A | $494K380,000 at $1.30 | filing |
| 25 Sep 2015filed 28 Sep 2015 | VaxartBiotechnology | SEC FORM 4 Bought | $4,7252,500 at $1.89 | filing |
| 25 Sep 2015filed 28 Sep 2015 | VaxartBiotechnology | SEC FORM 4 Bought | $4,6252,500 at $1.85 | filing |
| 11 Aug 2015filed 13 Aug 2015 | Vaxartoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 27 Mar 2015filed 31 Mar 2015 | VaxartBiotechnology | SEC FORM 4 Bought | $23K10,000 at $2.27 | filing |
| 27 Mar 2015filed 31 Mar 2015 | VaxartBiotechnology | SEC FORM 4 Bought | $23K10,000 at $2.30 | filing |
| 1 Oct 2014filed 2 Oct 2014 | Vaxartoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.2M475,000 at $2.45 | filing |
| 30 Jun 2014filed 2 Jul 2014 | VaxartBiotechnology | SEC FORM 4 Bought | $29K10,000 at $2.86 | filing |
| 27 Jun 2014filed 30 Jun 2014 | VaxartBiotechnology | SEC FORM 4 Bought | $12K4,200 at $2.81 | filing |
News
No headline names them, or the companies they trade most, lately.